Black Patients With Merkel Cell Carcinoma Experience Treatment Delays
Factors associated with delays in treatment for patients with Merkel cell carcinoma were investigated.
Skin Cancer
T-VEC Shows Promise as Neoadjuvant Therapy in Melanoma
Investigators compared recurrence-free survival and overall survival outcomes in patients randomly assigned to receive neoadjuvant talimogene laherparepvec (T-VEC) followed by immediate surgery or surgery alone.
Reflectance Confocal Microscopy vs Biopsy for Diagnosis of Basal Cell Carcinoma
The sensitivity of reflectance confocal microscopy is evaluated in the context of basal cell carcinoma diagnosis.
A Statistical Fallacy Might Mar Study Findings on Bevacizumab in Melanoma
“‘Trended strongly’ is code for ‘we failed to meet statistical significance,’” remarked one expert, when she was asked to scrutinize the conclusions of a recent post hoc analysis.
G-CSF Pretreatment Ameliorates the Activity of an Autologous DC-Based Vaccine in Melanoma
Pretreatment with G-CSF prior to receiving an autologous DC-based vaccine resulted in worse outcomes compared with no G-CSF, according to results of a phase 2b study.
Neoadjuvant CMP-001 Plus Nivolumab Found Active in Stage III Melanoma
Neoadjuvant CMP-001 plus nivolumab demonstrated antitumor activity and upregulated the intratumor immune response in patients with stage III melanoma.
BEMPEG Plus Nivolumab Induces Durable Responses in Metastatic Melanoma
BEMPEG combined with nivolumab resulted in deep and durable responses among patients with treatment-naive metastatic melanoma, according to phase 2 data.
Risk of Melanoma Measured in Mutation Burden of Skin Cells
Mutation count could offer personal screening guidelines.
Research Shows Long-Term Benefit for Adjuvant Targeted Therapies in High-Risk Melanoma
More than half of patients with resected stage 3 melanoma with BRAF V600E or V600K mutations receiving a year’s worth of adjuvant dabrafenib and trametinib were still alive 5 years later.
How Do Melanoma Comorbidities Affect Patient Treatment Preferences?
Comorbidities can have an impact on what you as a medical professional think is the best course of treatment for your patients. Can they also affect a patient’s thinking on treatment? Comorbidities such as cardiovascular disease, hypertension, and depression can contribute to how a patient’s body responds to treatment and its attendant stress. A recent…
-
Loading...
-
Loading...
